SecBot SecBot
6-K ·Filed May 4, 2026

DRTSW

Alpha Tau Medical Ltd.
BULLISH
Impact 7/10
Horizondays Processed6mo ago SEC0001213900-26-051176
Notable filing: 6-K
Actionable Insight ▲ Bullish

The strong efficacy and safety data could drive near-term stock appreciation. Monitor for updates on the U.S. IMPACT trial enrollment and any regulatory interactions. Given the company's small market cap and early-stage pipeline, this is a high-risk/high-reward catalyst.

DirectionBullish
Confidencehigh
Horizondays

How the stock moved after the report

⚠ Clustered BULLISH VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$1.02
T+0 close · May 4, 2026 · via day close
Latest settled
+124.51%
T+60 · $2.29
Vs SPY
+122.65%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · May 4 $1.02entry
  2. T+1 · 7mo ago 0.00%α −0.80% · $1.02
  3. T+5 · 6mo ago 0.00%α −2.94% · $1.02
  4. T+20 · 6mo ago 0.00%α −5.65% · $1.02
  5. T+60 · 4mo ago +124.51%α +122.65% · $2.29

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Alpha Tau announced positive clinical trial results for its Alpha DaRT therapy in pancreatic cancer, achieving 100% local disease control in 19 evaluable patients with a favorable safety profile. These results were presented at DDW 2026 and support the ongoing U.S. multicenter IMPACT trial, representing a significant milestone for the pre-commercialization biotech.

Key Facts

  • 100% local disease control rate in evaluable patients from pooled analysis of two first-in-human trials of Alpha DaRT in pancreatic adenocarcinoma
  • 15 of 19 evaluable patients (79%) achieved stable disease and 4 (21%) had partial response per modified RECIST v1.1
  • Only 8 device-associated adverse events in 7 of 26 subjects (27%), nearly all resolving within two weeks
  • Results presented at Digestive Disease Week (DDW) 2026, first oral presentation at a major gastroenterology conference
  • Data supports ongoing U.S. multicenter pancreatic cancer IMPACT trial

Financial Impact

No financial figures provided; clinical milestone for pre-revenue company with $117M market cap

Risk Factors

  • Early-stage clinical data with small sample size (n=19 evaluable) may not predict larger trial outcomes
  • Alpha DaRT is not yet approved for commercial use in the U.S. or elsewhere
  • Company has limited operating history and has incurred significant losses; may require additional funding

Market Snapshot

Exchange
Nasdaq
Sector
Surgical & Medical Instruments & Apparatus

Investment Themes

Healthcare & Medical Devices

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
6-K Filing (Primary)0001213900-26-051176
Document: ea0288785-6k_alphatau.htm0001213900-26-051176
Document: 0001213900-26-051176-index-headers.html0001213900-26-051176
Document: 0001213900-26-051176-index.html0001213900-26-051176
Document: 0001213900-26-051176.txt0001213900-26-051176

Track record

14 reports on DRTSW

Performance horizon

8 of 8 bullish or bearish reports moved the stock their way by T+60. Best: +292.16% at T+60 after the Jun 3, 2026 report. 8 of 8 went positive at some point.

Filters
  1. Jun 3, 202623w ago 6-K Bullish 7/10 Entry $1.02 to $4.00 ▲ +292.16% +289.66% vs SPY
  2. Jun 1, 202624w ago 6-K Bullish 7/10 Entry $1.02 to $3.89 ▲ +281.37% +280.14% vs SPY
  3. May 18, 202626w ago 6-K Neutral 5/10 Entry $1.02 to $3.89 ▲ +281.37% +275.08% vs SPY
  4. May 11, 202627w ago 6-K Bullish 7/10 Entry $1.02 to $3.37 ▲ +230.39% +226.00% vs SPY
  5. May 11, 202627w ago 6-K Bullish 6/10 Entry $1.02 to $3.37 ▲ +230.39% +226.00% vs SPY
  6. May 8, 202627w ago 6-K Neutral 3/10 Entry $1.02 to $3.30 ▲ +223.53% +218.69% vs SPY
  7. May 8, 202627w ago 6-K Bullish 6/10 Entry $1.02 to $3.30 ▲ +223.53% +218.69% vs SPY
  8. May 7, 202627w ago 6-K Neutral 3/10 Entry $1.02 to $2.58 ▲ +152.94% +149.11% vs SPY
  9. May 5, 202627w ago 6-K Neutral 3/10 Entry $1.02 to $2.70 ▲ +164.71% +161.97% vs SPY
  10. May 4, 202628w ago 6-K Bullish 7/10 Viewing Entry $1.02 to $2.29 ▲ +124.51% +122.65% vs SPY
Showing 10 of 14

US Market Status

Market Closed · Opens in 8h 46m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published May 4, 2026